206 related articles for article (PubMed ID: 25456076)
1. An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
Reddy KI; Srihari K; Renuka J; Sree KS; Chuppala A; Jeankumar VU; Sridevi JP; Babu KS; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Dec; 22(23):6552-6563. PubMed ID: 25456076
[TBL] [Abstract][Full Text] [Related]
2. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
Jeankumar VU; Renuka J; Santosh P; Soni V; Sridevi JP; Suryadevara P; Yogeeswari P; Sriram D
Eur J Med Chem; 2013; 70():143-53. PubMed ID: 24148991
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
[TBL] [Abstract][Full Text] [Related]
4. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
Medapi B; Suryadevara P; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
Eur J Med Chem; 2015 Oct; 103():1-16. PubMed ID: 26318054
[TBL] [Abstract][Full Text] [Related]
5. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
[TBL] [Abstract][Full Text] [Related]
6. Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
Bobesh KA; Renuka J; Srilakshmi RR; Yellanki S; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2016 Jan; 24(1):42-52. PubMed ID: 26678175
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
Medapi B; Renuka J; Saxena S; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 May; 23(9):2062-78. PubMed ID: 25801151
[TBL] [Abstract][Full Text] [Related]
9. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
[TBL] [Abstract][Full Text] [Related]
10. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling.
Jeankumar VU; Reshma RS; Janupally R; Saxena S; Sridevi JP; Medapi B; Kulkarni P; Yogeeswari P; Sriram D
Org Biomol Chem; 2015 Feb; 13(8):2423-31. PubMed ID: 25569565
[TBL] [Abstract][Full Text] [Related]
11. Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
Bobesh KA; Renuka J; Jeankumar VU; Shruti SK; Sridevi JP; Yogeeswari P; Sriram D
Eur J Med Chem; 2014 Oct; 85():593-604. PubMed ID: 25127151
[TBL] [Abstract][Full Text] [Related]
12. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
Kale MG; Raichurkar A; P SH; Waterson D; McKinney D; Manjunatha MR; Kranthi U; Koushik K; Jena Lk; Shinde V; Rudrapatna S; Barde S; Humnabadkar V; Madhavapeddi P; Basavarajappa H; Ghosh A; Ramya VK; Guptha S; Sharma S; Vachaspati P; Kumar KN; Giridhar J; Reddy J; Panduga V; Ganguly S; Ahuja V; Gaonkar S; Kumar CN; Ogg D; Tucker JA; Boriack-Sjodin PA; de Sousa SM; Sambandamurthy VK; Ghorpade SR
J Med Chem; 2013 Nov; 56(21):8834-48. PubMed ID: 24088190
[TBL] [Abstract][Full Text] [Related]
13. Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
Medapi B; Meda N; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2016 Feb; 24(4):877-85. PubMed ID: 26787274
[TBL] [Abstract][Full Text] [Related]
14. Novel amide and sulphonamide derivatives of 6-(piperazin-1-yl)phenanthridine as potent Mycobacterium tuberculosis H37Rv inhibitors.
Naidu KM; Nagesh HN; Singh M; Sriram D; Yogeeswari P; Gowri Chandra Sekhar KV
Eur J Med Chem; 2015 Mar; 92():415-26. PubMed ID: 25590862
[TBL] [Abstract][Full Text] [Related]
15. Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.
Kale RR; Kale MG; Waterson D; Raichurkar A; Hameed SP; Manjunatha MR; Kishore Reddy BK; Malolanarasimhan K; Shinde V; Koushik K; Jena LK; Menasinakai S; Humnabadkar V; Madhavapeddi P; Basavarajappa H; Sharma S; Nandishaiah R; Mahesh Kumar KN; Ganguly S; Ahuja V; Gaonkar S; Naveen Kumar CN; Ogg D; Boriack-Sjodin PA; Sambandamurthy VK; de Sousa SM; Ghorpade SR
Bioorg Med Chem Lett; 2014 Feb; 24(3):870-9. PubMed ID: 24405701
[TBL] [Abstract][Full Text] [Related]
16. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
Jeankumar VU; Kotagiri S; Janupally R; Suryadevara P; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 Feb; 23(3):588-601. PubMed ID: 25541204
[TBL] [Abstract][Full Text] [Related]
17. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Hameed P S; Patil V; Solapure S; Sharma U; Madhavapeddi P; Raichurkar A; Chinnapattu M; Manjrekar P; Shanbhag G; Puttur J; Shinde V; Menasinakai S; Rudrapatana S; Achar V; Awasthy D; Nandishaiah R; Humnabadkar V; Ghosh A; Narayan C; Ramya VK; Kaur P; Sharma S; Werngren J; Hoffner S; Panduga V; Kumar CN; Reddy J; Kumar K N M; Ganguly S; Bharath S; Bheemarao U; Mukherjee K; Arora U; Gaonkar S; Coulson M; Waterson D; Sambandamurthy VK; de Sousa SM
J Med Chem; 2014 Jun; 57(11):4889-905. PubMed ID: 24809953
[TBL] [Abstract][Full Text] [Related]
18. Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors.
Salve PS; Alegaon SG; Sriram D
Bioorg Med Chem Lett; 2017 Apr; 27(8):1859-1866. PubMed ID: 28274627
[TBL] [Abstract][Full Text] [Related]
19. In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations.
Kamsri P; Punkvang A; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
SAR QSAR Environ Res; 2019 Nov; 30(11):775-800. PubMed ID: 31607177
[No Abstract] [Full Text] [Related]
20. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
Chaudhari K; Surana S; Jain P; Patel HM
Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
